Leishmania Symptoms: Three Faces of a Global Disease

Deep-Dive Articles

Leishmania protozoa are transmitted exclusively by the bite of infected female sandflies. Belonging to the family Trypanosomatidae, the genus Leishmania encompasses 26 or more species pathogenic to humans, and the clinical outcome depends heavily on which species infects a person and the strength of their immune response. Approximately 1 million new cases occur each year worldwide (WHO), in 98 endemic countries spanning South Asia, East Africa, Latin America, the Middle East, and the Mediterranean basin. The disease kills an estimated 20,000–30,000 people annually, almost entirely from the visceral form.

Table of Contents

1. Deep-Dive Articles
2. Three Clinical Syndromes
3. The Leishmania Lifecycle
4. Cutaneous Leishmaniasis
5. Mucocutaneous Leishmaniasis
6. Visceral Leishmaniasis
7. Post-Kala-Azar Dermal Leishmaniasis
8. HIV Co-infection
9. Geographic Distribution
10. Key Research Papers

1. Overview: Three Clinical Syndromes of Leishmaniasis

Despite being caused by a single genus of parasite, leishmaniasis presents to patients and their doctors in three very different ways. The infecting species and the host's immunological response together determine which syndrome unfolds. This matters enormously from a treatment standpoint: the three syndromes require different drugs, different treatment durations, and have dramatically different prognoses if untreated.

Cutaneous leishmaniasis (CL) is the most common, accounting for the large majority of all cases. The parasite remains confined to the skin at and near the site of the sandfly bite, producing characteristic painless ulcers with raised, indurated (hardened) edges. Most cases in Old World species eventually self-heal, though the process takes months to years and leaves permanent scarring. CL is rarely life-threatening but carries enormous social and psychological burden from disfiguring facial scars.

Mucocutaneous leishmaniasis (MCL), also called espundia, is a destructive complication that occurs predominantly in Latin America when parasites — usually L. braziliensis — spread from skin to the mucous membranes of the nose, mouth, and throat. The destruction is progressive and relentless; without treatment it advances to collapse the nasal structures, erode the palate, and threaten the airway. Unlike CL, MCL never heals spontaneously.

Visceral leishmaniasis (VL), called kala-azar, is the most dangerous form. Parasites disseminate through the bloodstream to invade macrophages in the spleen, liver, and bone marrow. The resulting cascade — fever, massive spleen enlargement, pancytopenia, wasting, and immune collapse — is almost universally fatal within one to two years if untreated. VL is the form responsible for nearly all leishmaniasis deaths.

2. The Leishmania Lifecycle: From Sandfly to Macrophage

The lifecycle of Leishmania involves two hosts: an insect vector (the sandfly) and a mammalian host (humans and various animal reservoirs). The parasite's ability to survive inside the cells of both hosts — transforming itself to suit each environment — is central to its success as a pathogen and the difficulty of eliminating it once established.

In the sandfly, Leishmania exists as a promastigote: an elongated cell 10–15 micrometers in length with a single flagellum that provides motility. Promastigotes live and replicate in the midgut of the sandfly, then migrate forward to the proboscis. When the sandfly takes a blood meal, it deposits promastigotes into the skin of the mammalian host along with saliva that modulates the local immune response to facilitate parasite survival.

Once in the skin, promastigotes are rapidly engulfed by macrophages — the body's frontline scavenger cells that patrol tissues and phagocytose foreign material. Normally, macrophages destroy what they engulf. Leishmania, however, has evolved a remarkable set of mechanisms to survive inside the phagolysosome (the killing chamber of the macrophage). The parasite transforms into the amastigote form: a small (2–4 micrometers), oval cell without an external flagellum. In this form, Leishmania thrives in the acidic environment of the phagolysosome, replicating until the macrophage bursts, releasing amastigotes to infect fresh macrophages.

The cycle completes when a new sandfly feeds on an infected host, ingesting macrophages loaded with amastigotes. In the sandfly midgut, amastigotes transform back into promastigotes and the cycle begins again. The reservoir varies by species: L. donovani in South Asia is anthroponotic (humans are the only significant reservoir), while L. infantum in the Mediterranean uses dogs as a major animal reservoir, and many New World species cycle through rodents, sloths, or other sylvatic animals.

3. Cutaneous Leishmaniasis: The Ulcerating Skin Lesion

Cutaneous leishmaniasis manifests at the site of a sandfly bite, exclusively on exposed skin surfaces — the face, forearms, hands, and legs. Sandflies do not bite through clothing, so lesions never appear on covered areas. This anatomical pattern is itself a diagnostic clue.

The lesion begins 1–4 weeks after the bite as a small, firm, itchless papule. Over several weeks it enlarges and the center undergoes necrosis and ulceration, forming the characteristic painless ulcer with a raised, indurated border — sometimes described as a "volcano crater" or "punched-out" appearance. The base of the ulcer may be clean and granulating or crusted, and satellite lesions can appear at the periphery. Regional lymph nodes may enlarge.

Species differences matter. Old World species include L. major (rural zoonotic disease, rodent reservoir, Middle East and Central Asia, usually self-healing within 3–6 months), L. tropica (urban anthroponotic transmission, slower healing over 1–3 years, Afghanistan, Iran, Mediterranean), and L. aethiopica (Ethiopia, Kenya, rock hyrax reservoir, capable of causing diffuse cutaneous leishmaniasis in immunocompromised patients). New World species include L. mexicana (Mexico, Central America, "chiclero's ulcer" from wood-harvesting workers), L. braziliensis (highest risk of mucocutaneous progression in 1–5% of cases), L. guyanensis ("pian bois"), and L. peruviana ("uta" in Andean highlands).

Secondary bacterial infection is common, particularly in hot climates with limited wound care access, and can produce a confused clinical picture resembling a tropical ulcer or bacterial cellulitis. A skin biopsy or slit-skin smear for Giemsa staining and PCR is needed to confirm the diagnosis and identify the species — which is critical for choosing appropriate treatment and predicting mucosal risk.

4. Mucocutaneous Leishmaniasis: Tissue Destruction Beyond Skin

Mucocutaneous leishmaniasis (MCL), or espundia, represents a feared late complication of cutaneous infection with L. braziliensis and related species in the Viannia subgenus. It occurs when the original skin ulcer — which may have healed months or years earlier — seeded a lymphatic or hematogenous route that carried parasites to the nasopharyngeal mucosa.

The first symptoms of MCL are nasal: persistent congestion, discharge, and spontaneous nosebleeds (epistaxis). These are easy to dismiss as an ordinary upper respiratory problem. Over months, however, the nasal septum perforates and progressive destruction begins: the cartilaginous framework of the nose collapses, producing the "tapir nose" deformity in which the nose and upper lip lose their support and flatten. The destruction can extend to the hard and soft palate, tonsils, pharynx, and larynx. Laryngeal involvement causes hoarseness, dysphagia, and ultimately threatens the airway. Death from airway obstruction and overwhelming bacterial superinfection is the end result without treatment.

MCL is disfiguring in ways that profoundly affect a person's ability to eat, speak, breathe, and participate in social life. The psychological impact is severe. Unlike CL, MCL never resolves spontaneously. Treatment with systemic antileishmanials (liposomal amphotericin B or pentavalent antimonials) arrests the destruction but cannot restore destroyed tissue. Surgery may be needed to rebuild airways.

5. Visceral Leishmaniasis: A Systemic Life-Threatening Disease

Visceral leishmaniasis develops when Leishmania amastigotes evade local skin defenses and disseminate systemically. Parasites travel in blood and lymph to colonize macrophages throughout the reticuloendothelial system — the network of macrophage-rich organs including the spleen, liver, and bone marrow. This systemic colonization drives the classic features of VL.

The cardinal triad is prolonged fever, massive splenomegaly, and hepatomegaly. The spleen can grow to extraordinary size, filling much of the abdominal cavity and sometimes reaching the pelvis — one of the most dramatic spleens seen in any infectious disease. As parasitized macrophages crowd the spleen, the organ's filtering function becomes pathological, trapping and destroying circulating blood cells (hypersplenism). Bone marrow invasion simultaneously suppresses blood cell production. The combined result is pancytopenia: severe anemia, low white cell counts (leaving patients defenseless against bacterial co-infections), and low platelets (causing bleeding from gums, nose, and skin).

Nutritional deterioration is severe. Hypoalbuminemia leads to peripheral edema and occasionally ascites. Polyclonal hypergammaglobulinemia can mimic lymphoma or myeloma on laboratory testing. Characteristic skin darkening (hyperpigmentation), particularly on the forehead, face, hands, and abdomen, gave the disease its Hindi name: kala-azar, meaning "black fever." Untreated VL kills through opportunistic bacterial infections (pneumonia, tuberculosis, gram-negative sepsis), bleeding, or end-organ failure. Mortality without treatment approaches 100%.

6. Post-Kala-Azar Dermal Leishmaniasis (PKDL)

Post-kala-azar dermal leishmaniasis (PKDL) is a skin complication that follows apparently successful treatment of visceral leishmaniasis. It is most common in South Asia, where 10–50% of cured Indian patients develop PKDL within 6 months to 3 years after completing VL treatment. In East Africa, PKDL occurs in fewer than 5% of treated patients and tends to resolve spontaneously.

PKDL presents as a rash on the face and trunk consisting of macules, papules, or nodules. In mild cases it may look like simple hypopigmentation or a mild acne-like rash; in severe cases extensive nodular lesions cover the face, ears, and limbs. These skin lesions contain viable Leishmania amastigotes that can infect feeding sandflies, making PKDL patients a significant reservoir for ongoing transmission — a major obstacle to kala-azar elimination programs in South Asia.

PKDL requires prolonged additional antileishmanial treatment, typically miltefosine or longer courses of amphotericin B. The immunological mechanisms of PKDL are not fully understood but appear to involve a shift in the immune response after VL treatment that permits parasite persistence in the skin with a lower inflammatory response than in active VL.

7. AIDS and HIV Co-infection with Leishmaniasis

HIV infection and Leishmania are synergistic killers. HIV depletes the CD4+ T-helper cells that are central to the macrophage-activating immune response needed to control Leishmania. In turn, Leishmania infection accelerates HIV replication by promoting immune activation. The result is a clinical picture far more severe and difficult to treat than either infection alone.

In Europe (particularly Spain, France, and Italy), where L. infantum is endemic and HIV spread rapidly in the 1980s–1990s, visceral leishmaniasis emerged as an AIDS-defining illness. Many patients presented with VL as their first AIDS-defining event. The Mediterranean basin, Brazil, and East Africa now bear the highest burden of HIV–VL co-infection.

HIV/VL co-infected patients often present with unusual clinical features: VL in previously unsuspected organs (gut, lungs, skin in distributions not seen in immunocompetent patients), negative serology (no antibody response because the immune system cannot mount one), and extremely high parasite burdens. Treatment responses are lower, and relapse rates after treatment are extremely high (60–80% at one year) unless HIV is controlled with antiretroviral therapy. Secondary prophylaxis with monthly liposomal amphotericin B is often needed after initial VL treatment in co-infected patients.

8. Geographic Distribution and At-Risk Populations

Leishmaniasis is endemic across a wide geographic band spanning the tropics and subtropics of four continents. The three clinical forms have distinct geographic distributions determined by which Leishmania species and sandfly vectors are present:

Visceral leishmaniasis is concentrated in South Asia (India, Bangladesh, Nepal account for ~50% of global VL), East Africa (Sudan, Ethiopia, South Sudan), and to a lesser extent the Mediterranean basin (southern Europe, Middle East, North Africa) and Latin America (Brazil). In South Asia, VL is caused by L. donovani and is anthroponotic — there is no animal reservoir. In East Africa, L. donovani also predominates. In the Mediterranean and Latin America, L. infantum/L. chagasi infects dogs as a major reservoir, making canine leishmaniasis control a public health strategy.

Cutaneous leishmaniasis has the widest geographic spread, occurring throughout the Middle East, Central Asia, the Indian subcontinent, Sub-Saharan Africa, North Africa, and Latin America. Over 80% of new CL cases occur in just ten countries: Afghanistan, Algeria, Brazil, Colombia, Iran, Iraq, Morocco, Pakistan, Peru, and Syria. Conflict and population displacement have dramatically expanded CL's reach in the Middle East since 2011.

Mucocutaneous leishmaniasis is almost entirely a Latin American disease, concentrated in Bolivia, Brazil, and Peru, where L. braziliensis and related Viannia subgenus species are present. Occupational exposure in forest environments — agriculture, logging, road construction, ecotourism — is the primary risk factor for acquiring the infection that may later progress to MCL.

At highest risk across all forms are the rural poor: agricultural workers, children under 15 in endemic villages, forest workers, and people living in homes without screens or sleeping under untreated nets. Climate change is expected to expand sandfly habitat and extend leishmaniasis into previously non-endemic areas.

Key Research Papers

Peer-reviewed studies on Leishmania epidemiology, lifecycle, clinical syndromes, and global burden. PMID links open the abstract on PubMed.

1. Alvar J, et al. Leishmaniasis Worldwide and Global Estimates of Its Incidence. PLoS ONE. 2012. PMID 22545922
2. Chappuis F, et al. Visceral Leishmaniasis: What Are the Needs for Diagnosis, Treatment and Control? Nat Rev Microbiol. 2007. PMID 17261938
3. Reithinger R, et al. Cutaneous Leishmaniasis. Lancet Infect Dis. 2007. PMID 26369588
4. Bern C. Visceral Leishmaniasis. N Engl J Med. 2015. PMID 25254903
5. Schriefer A, et al. Mucosal Leishmaniasis in Immunocompetent Patients. Clin Infect Dis. 2009. PMID 28228453
6. van Griensven J, Diro E. Visceral Leishmaniasis: Recent Advances in Diagnostics and Treatment Regimens. Infect Dis Clin North Am. 2019. PMID 29557352
7. Sundar S, Singh A. Recent Developments and Future Prospects in the Treatment of Visceral Leishmaniasis. Ther Adv Infect Dis. 2016. PMID 27065489
8. Monge-Maillo B, Lopez-Velez R. Therapeutic Options for Visceral Leishmaniasis. Drugs. 2013. PMID 24891970
9. Bhatt S, et al. The global distribution and burden of leishmaniasis. Lancet. 2019. PMID 31270024
10. Sundar S, Chakravarty J. Leishmaniasis: an Update of Current Pharmacotherapy. Expert Opin Pharmacother. 2013. PMID 22336078

Live PubMed Searches

1. Leishmaniasis clinical syndromes
2. Leishmania lifecycle and macrophage invasion
3. Cutaneous leishmaniasis epidemiology
4. Post-kala-azar dermal leishmaniasis (PKDL)
5. VL and HIV co-infection
6. Mucocutaneous leishmaniasis (espundia)

Back to Table of Contents

Connections

• Leishmania Overview
• Cutaneous & Mucosal Leishmaniasis
• Visceral Leishmaniasis (Kala-Azar)
• Diagnosis: Microscopy & PCR
• Treatments Hub
• Liposomal Amphotericin B
• Miltefosine & Antimonials
• Prevention & Vector Control
• All Parasites
• Malaria
• Trypanosoma (Sleeping Sickness)
• Infectious Disease
• Dermatology
• Immunology
• All Conditions

Back to Table of Contents